Greywolf Reports Durable Responses with First-in-Class ERAP1 Inhibitor
OXFORD, UK, May 22, 2026 Greywolf Therapeutics announced encouraging clinical results from the Phase 1b portion of its ongoing...
solid tumors
Advertisement
Antengene Expands Oncology Pipeline With Phase III ATG-022 Gastric Cancer Trial
SHANGHAI and HONG KONG, China, May 28, 2026 Antengene has announced a major clinical development milestone after receiving endorsement...
Anaveon Reports Promising Phase 1 ANV600 Cancer Data at ASCO 2026
BASEL, Switzerland — May 28, 2026 Anaveon announced new clinical data from its Phase 1 EXPAND-1 trial showing encouraging...
Brenus Pharma Wins FDA IND Clearance for STC-1010
LYON, France — May 28, 2026 Brenus Pharma announced that the U.S. Food and Drug Administration has accepted the...
Citius Oncology LYMPHIR ASCO Phase 1 Data
CRANFORD, New Jersey, May 26, 2026 Citius Oncology, Inc. has announced that new Phase 1 clinical study data evaluating...
Advertisements
Adcendo and MSD Expand KEYTRUDA Cancer Trial
COPENHAGEN, Denmark, May 26, 2026 Adcendo ApS has announced a new clinical collaboration and supply agreement with MSD (Merck...
A2 Bio Reports First CAR-T Complete Response in Lung Cancer
CHICAGO, Illinois, 21 May 2026 A2 Biotherapeutics, Inc. announced new safety and efficacy results from its ongoing EVEREST-2 Phase...
BioLineRx and Hemispherian Showcase GLIX1 Cancer Data at ASCO 2026
Tel Aviv, Israel and Oslo, Norway – May 22, 2026 BioLineRx Ltd. and Hemispherian AS announced new preclinical and...
Datar Cancer Genetics Receives Landmark FDA Approval for CellDx-Tissue
NASHIK, India, May 21, 2026 Datar Cancer Genetics (DCG) has achieved a major milestone in precision oncology after receiving...
Orion Pharma Presents First ODM-212 Cancer Trial Data at ASCO 2026
ESPOO, Finland, May 21, 2026 Orion Pharma announced that it will present the first clinical data from its ongoing...
Advertisement
